Loading the session
Loading the session
Loading instrument
$6.53
−3.40%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 22:51 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 close of $6.76 was 10.7% below its 50-day average ($7.57) and 7.1% below its 200-day average ($7.28). It has closed below the 200-day for 5 sessions, since 29 Oct 2026. The 50-day average crossed above the 200-day on 5 Oct 2026, 22 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.5M shares were sold short at the 15 Oct 2026 settlement, 10.1% of the 65.0M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: −12.7% (SPY −1.6%). 3 months: +4.3% (SPY −0.4%). 1 year: +24.0% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EPRX, SPY · as of 4 Nov 2026
Closed at $6.76 on 4 Nov 2026: 27.5% below the 52-week high of $9.32 (21 Jan 2026) and 28.8% above the low of $5.25 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
September 2, 2026
+17.51%January 8, 2026
+19.14%November 1, 2024
+24.00%